Thank you for registering your account
Thanks for joining touchENDOCRINOLOGY to hear about news and updates from across the Endocrinology community.
We’ve sent you an email to verify your email address. Please click on the link to confirm your account.
You can review your email preferences at any time or update your account details
Continuing the conversation in growth hormone disorders – how do we progress towards personalized medicine for patients with acromegaly?
Stay up to date with the latest developments in the diagnosis, management and treatment of patients with acromegaly with our expert summary from the European Congress of Endocrinology (ECE) in Lyon, France, 18–21 May 2019. Part 1: Watch internationally renowned expert Prof. John Wass review key data from ECE2019 Part 2: Choose from leading experts who discuss what the data findings mean for global and regional practice
- Interpret the latest information and guidance about the need for early diagnosis and monitoring of acromegaly
- Recall the most recent data around patient and disease characteristics, including the importance of recognizing comorbidities, in order to select the optimal treatment strategy for each individual patient with acromegaly
- Recognize the role of medical treatment options for acromegaly and best practice for patient management using a multidisciplinary team approach
Samuel Dagogo-Jack, ADA 2022: A study highlighting the association of sphingolipids with prediabetes risk – potential biomarkers?
Species of sphingolipids have been associated with prediabetes risk. Dr Samuel Dagogo-Jack (University of Tennessee Health Science Center, Memphis, TN, USA) discusses the outcome of a longitudinal study conducted at the University of Tennessee which followed a diverse cohort of patients who initially presented with ‘normal’ glucose metabolism but bifurcated into two subgroups: those with […]
Samuel Dagogo-Jack, ADA 2022: Highlights and hot topics in the field of diabetes
The key trials in the field of diabetes, including the results of the tirzepatide study, presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022, are discussed by Dr Samuel Dagogo-Jack (University of Tennessee Health Science Center, Memphis, TN, USA). Questions: What were your highlights from the ADA meeting? (0:37) Disclosures: Samuel Dagogo-Jack […]
Riccardo Candido, ADA 2022: Intensification strategies following GLP1-RA therapy failure in type 2 diabetes, the RESTORE-G real-world study
The RESTORE-G real-world study investigated the intensification strategies following GLP1-RA therapy failure in type 2 diabetes. Dr Riccardo Candido (Diabetes Center District 4, ASUGI, Trieste, Italy) discusses the design of the study, the key findings and the implications for clinical practice. The abstract entitled ‘Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 […]
Watch out for Danatech! The latest online resource for diabetes healthcare professionals
touchENDOCRINOLOGY spoke to Leslie Kolb (Chief Science Practice and Learning Officer) and Dana Moreau (Senior Product Manager of Danatech) from the Association of Diabetes Care and Education Specialists (ADCES) to discuss the exciting launch of Danatech. This innovative online resource allows healthcare professionals to research and review the latest devices and mobile apps and offers […]
Use of Continuous Glucose Monitoring in Older Adults: A Review of Benefits, Challenges and Future Directions
touchREVIEWS in Endocrinology. 2022;18(2):116–21 DOI: https://doi.org/10.17925/EE.2022.18.2.116
Recent advances in technology have changed the landscape for managing diabetes treatment. Thanks to innovations such as connected insulin pens, sensor-augmented pump systems, automated insulin delivery, integrated mobile applications and continuous glucose monitoring (CGM) systems, people with diabetes now have access to devices that are easier to use and far less invasive than those available […]
Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors
touchREVIEWS in Endocrinology. 2022;18(2):106-15 DOI: https://doi.org/10.17925/EE.2022.18.2.106
Over 37 million people in the USA live with diabetes mellitus, equating to over 11% of the population.1 The large majority of these individuals (around 90–95%) have type 2 diabetes (T2D).1 Approximately 40% of patients T2D develop chronic kidney disease (CKD), with CKD in diabetes being the leading cause of kidney failure and need for kidney-replacement therapy […]
Review of the Function of the Hypothalamic–Pituitary–Gonadal Axis in Children and Adolescents with Cancer
touchREVIEWS in Endocrinology. 2022;17(2):122-32 DOI: https://doi.org/10.17925/EE.2022.18.2.122
The development of effective therapies for the management of cancer in childhood has led to outstanding improvements in survival over the past decades. With this, a growing population of childhood cancer survivors are subject to long-term sequelae impacting on health. Endocrine disorders, and especially reproductive function in adulthood, have become an important concern.1 There is a […]
Assessing the Incidence of New-onset Diabetes Mellitus with Statin Use: A Systematic Review of the Systematic Reviews and Meta-analyses
touchREVIEWS in Endocrinology. 2022;18(2):96-101 DOI: https://doi.org/10.17925/EE.2022.18.2.96
Recently, concern has been raised that statin therapy may be associated with new-onset diabetes mellitus (NODM), especially given the wide usage of statins in the treatment of dyslipidaemia and cardiovascular diseases (CVD). Statins have been found to affect not only the functioning of the beta cells of the pancreas, but their use also leads to […]